Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

  • Discontinued
  • GID-TA11005

27748-Lenvatinib-with-Pembrolizumab-for-Squamous-Cell-Carcinoma-of-the-Head-and-Neck-V1.0-FEB2022-NONCONF.pdf (nihr.ac.uk)